Pharmacogenetics studies in STAR*D: strengths, limitations, and results.

ABSTRACT: Several lines of evidence support an important genetic contribution to the wide individual variation in therapeutic response to antidepressant medications. The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study provided the largest cohort assembled to date of DNA from patients with nonpsychotic major depressive disorder, uniformly treated with citalopram and followed prospectively for up to 12 weeks. This pivotal study changed the face of pharmacogenetics research by increasing the sample size by an order of magnitude as well as by providing detailed prospective information about antidepressant response and tolerability. Several groups have identified markers in genes and tested the replication of previous findings of genes associated with outcome and side effects of ant

SUBMITTER: Laje G 

PROVIDER: S-EPMC3775610 | biostudies-literature | 2009 Nov

REPOSITORIES: biostudies-literature